Survivin分子信标检测膀胱尿路上皮癌的临床研究

目的研究Survivin分子信标检测膀胱尿路上皮癌的临床价值。方法收集280例血尿患者的尿液标本进行Survivin分子信标检测,其中膀胱尿路上皮癌177例,非膀胱尿路上皮癌患者103例。对73例膀胱尿路上皮癌患者的肿瘤组织进行免疫组织化学染色。结果 Survivin分子信标检测膀胱尿路上皮癌的灵敏度和特异度分别为81.4%和73.8%,免疫组织化学染色检测Survivin表达的阳性率是90.4%(66 of 73)。Survivin分子信标检测膀胱尿路上皮癌与患者的临床分期密切相关。结论 Survivin分子信标是一种具有较高灵敏度和特异度的检测膀胱尿路上皮癌的非侵入性检查方法,比尿脱落细胞学检查具有更高的灵敏度,有望成为一种检测膀胱尿路上皮癌和膀胱尿路上皮癌术后随访的新的检测手段。

A clinical study of Survivin Molecular Beacons as an Improved Method for the Detection of Bladder urothelial carcinoma

Objective To determine whether the survivin molecular beacons detection could serve as a reliable non-invasive urine assay for detection of bladder urothelial carcinoma. Methods A total of 280 fresh voided urine samples were collected from 177 patients with bladder cancer and 103 suspected cases of bladder urothelial carcinoma with hematuria. All urine samples were detected by survivin molecular beacons. The expression of survivin was detected by immunohistochemistry in 73 fresh tumor tissue samples. Results Survivin molecular beacons had 81.4% (144 of 177) sensitivity and 73.8% (76 of 103) specificity for bladder urothelial carcinoma detection. The positive rate of immunohistochemistry for bladder urothelial carcinoma detection was 90.4% (66 of 73). The survivin expression detected by molecular beacons in bladder urothelial carcinoma was closely related with clinical stage (P＜0.05). Conclusion Survivin molecular beacons is significantly more sensitive than cytology for bladder urothelial carcinoma detection and has the potential to become a novel non-invasive approach for early detection and follow-up of bladder urothelial carcinoma.